A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC — DELC

Castration Resistant Prostate Cancer (CRPC) Clinical Trial

Official title:
A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC

Status Completed

Clinical Trial Summary

This is a prospective observational study to evaluate effectiveness and safety of Enzalutamide for Castration Resistant Prostate Cancer (CRPC) patients who decided to administer Enzalutamide after anti-androgen therapy. CRPC Patients who are observed PSA or disease progression after anti-androgen therapy and decided to administrate Enzalutamide will dose the Enzalutamide 160 mg orally once daily and observed the practical treatment. Total research term is for 4 years, consists of 2-year case registration terms and 2-year observational terms.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02669147
Study type	Observational
Source	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Contact
Status	Completed
Phase
Start date	January 26, 2016
Completion date	March 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01911741` - A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects	Phase 1
Completed	`NCT01284920` - A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients	Phase 1/Phase 2
Completed	`NCT01911728` - Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates	Phase 1
Recruiting	`NCT03460977` - PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma	Phase 1